These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24101614)

  • 21. The evolving high: new designer drugs of abuse.
    Pourmand A; Armstrong P; Mazer-Amirshahi M; Shokoohi H
    Hum Exp Toxicol; 2014 Oct; 33(10):993-9. PubMed ID: 24501103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis.
    Thornton SL; Lo J; Clark RF; Wu AH; Gerona RR
    Clin Toxicol (Phila); 2012 Dec; 50(10):1165-8. PubMed ID: 23163617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New challenges in toxicology of new psychoactive substances exemplified by fatal cases after UR-144 and UR-144 with pentedrone administration determined by LC-ESI-MS-MS in blood samples.
    Rojek S; Korczyńska-Albert M; Kulikowska J; Kłys M
    Arch Med Sadowej Kryminol; 2017; 67(2):104-120. PubMed ID: 29363897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Spice drugs: cannabinoids as a new designer drugs].
    Mustata C; Torrens M; Pardo R; Pérez C; ; Farré M
    Adicciones; 2009; 21(3):181-6. PubMed ID: 19718488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective screening of synthetic cannabinoids, synthetic opioids and designer benzodiazepines in data files from forensic post mortem samples analysed by UHPLC-QTOF-MS from 2014 to 2018.
    Gundersen POM; Broecker S; Slørdal L; Spigset O; Josefsson M
    Forensic Sci Int; 2020 Jun; 311():110274. PubMed ID: 32302877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemorrhagic Highs from Synthetic Cannabinoids - A New Epidemic.
    Connors JM
    N Engl J Med; 2018 Sep; 379(13):1275-1277. PubMed ID: 30257159
    [No Abstract]   [Full Text] [Related]  

  • 27. Sample pooling as an effective way of simultaneous analysis of new designer drugs together with synthetic cannabinoids in human serum provided by therapy and forensic psychiatric centres.
    Dziadosz M; Klintschar M; Teske J
    Med Sci Law; 2016 Apr; 56(2):155-6. PubMed ID: 27044924
    [No Abstract]   [Full Text] [Related]  

  • 28. Development and Validation of a Novel All-Inclusive LC-MS-MS Designer Drug Method.
    Strickland EC; Cummings OT; Mellinger AL; McIntire GL
    J Anal Toxicol; 2019 Apr; 43(3):161-169. PubMed ID: 30462231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DART - LTQ ORBITRAP as an expedient tool for the identification of synthetic cannabinoids.
    Habala L; Valentová J; Pechová I; Fuknová M; Devínsky F
    Leg Med (Tokyo); 2016 May; 20():27-31. PubMed ID: 27161918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
    Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
    J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic cannabinoids: a new frontier of designer drugs.
    Gunderson EW
    Ann Intern Med; 2013 Oct; 159(8):563-4. PubMed ID: 24018791
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry.
    Shanks KG; Dahn T; Behonick G; Terrell A
    J Anal Toxicol; 2012 Jul; 36(6):360-71. PubMed ID: 22586208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic legal intoxicating drugs (April 2012).
    Chandiramani RN
    Cleve Clin J Med; 2012 Aug; 79(8):534; author reply 534-5. PubMed ID: 22854429
    [No Abstract]   [Full Text] [Related]  

  • 34. Understanding the dangers of synthetic cannabinoids.
    Lubarsky K; Odom A; Bernstein S; Kotbi N
    J Addict Med; 2014; 8(4):288-9. PubMed ID: 24755632
    [No Abstract]   [Full Text] [Related]  

  • 35. Coagulopathic hemorrhage with use of synthetic cannabinoids.
    Boyack I; Opsha O
    Am J Emerg Med; 2019 Feb; 37(2):374.e3-374.e4. PubMed ID: 30409461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data.
    Shevyrin V; Melkozerov V; Nevero A; Eltsov O; Baranovsky A; Shafran Y
    Forensic Sci Int; 2014 Nov; 244():263-75. PubMed ID: 25305529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Synthetic Cannabinoids Phenomenon.
    Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
    Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic drugs: time to ring the warning bell?
    Hassen GW; Kalantari H
    Am J Emerg Med; 2013 Dec; 31(12):1714-5. PubMed ID: 24157073
    [No Abstract]   [Full Text] [Related]  

  • 39. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids.
    Ammann J; McLaren JM; Gerostamoulos D; Beyer J
    J Anal Toxicol; 2012 Jul; 36(6):372-80. PubMed ID: 22593567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designer drugs. Patients may be using synthetic cannabinoids more than you think.
    Lisi DM
    JEMS; 2014 Sep; 39(9):56-9. PubMed ID: 25322519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.